Keywords: پسوریازیس; Acne vulgaris; Alexithymia; Alopecia areata; Psoriasis; Vitiligo;
مقالات ISI پسوریازیس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پسوریازیس; CCSA; Hair loss; Psoriasis; Scalp pruritus;
Keywords: پسوریازیس; Psoriasis; Angiogenesis; Inflammation; Cannabinoids; JWH-133;
Keywords: پسوریازیس; guttate psoriasis; HLA-C*06:02; psoriasis; ustekinumab; BSA; body surface area; HLA; human leukocyte antigen; IL; interleukin; PGA; physician global assessment; Th; T helper;
Keywords: پسوریازیس; Drug rash; eczema; erythroderma; psoriasis; suberythroderma;
Keywords: پسوریازیس; Diabetes; Psoriasis; Risk factor; Primary care;
Keywords: پسوریازیس; SÃndrome SAPHO; Psoriasis; Pústulas; Palmoplantar; SAPHO syndrome; Psoriasis; Pustular; Palmoplantar;
Keywords: پسوریازیس; psoriasis; pregnancy; lactation; biologic agents; TNF-alpha inhibitors;
Keywords: پسوریازیس; Multiple sclerosis; Psoriasis; Incidence; Prevalence; Validation;
Keywords: پسوریازیس; comorbidity; estrogen; psoriasis; schizophrenia; Th17Â cell;
Keywords: پسوریازیس; atopic dermatitis; cost of care; inflammatory skin disease; Medicare; prescription drug costs; psoriasis; topical immunomodulators; topical steroids; FM; family medicine; IM; internal medicine; MPUPD; Medicare Provider Utilization and Payment Data; psych/
Keywords: پسوریازیس; biologics; epidemiology; psoriasis; serious adverse infections; soft tissue infections; TNF-α; aHRs; adjusted hazard ratios; CI; confidence interval; IL; interleukin; IR; incidence rate; KPNC; Kaiser Permanente Northern California; SSTI; skin and soft ti
Keywords: پسوریازیس; Erectile Dysfunction; Psoriasis; Atopic Dermatitis; Cardiovascular Disease;
Keywords: پسوریازیس; cyclosporin; end-stage renal disease; psoriasis; renal disease;
Keywords: پسوریازیس; Psoriasis; Moderada-grave; Gravedad; Criterio; Moderada; Psoriasis; Moderate-to-severe; Severity; Criterion; Moderate;
Keywords: پسوریازیس; Artritis psoriásica; Psoriasis; Screening; Early Psoriatic Arthritis Screening Questionnaire; Adaptación cultural; Psoriatic arthritis; Psoriasis; Screening; EARP questionnaire; Cultural adaptation;
Keywords: پسوریازیس; arrhythmia; cardiovascular risk factors; comorbidities; diabetes; hyperlipidemia; hypertension; obesity; psoriasis; racial differences; ICD-9-CM; International Classification of Disease Ninth Clinical Modification; NIS; Nationwide Inpatient Sample;
Keywords: پسوریازیس; Psoriasis; Complementary medicine; Dietary supplements; Self-medication; Multivitamin;
Keywords: پسوریازیس; Psoriasis; Autoimmune disease; Metformin; Pioglitazone; CD4+ T cells; CD8+ T cells; Interleukin-2; C-reactive protein; Ceruloplasmin;
Keywords: پسوریازیس; Age of onset; Body image; Depression; Psoriasis; Social anxiety; Stigmatization;
Keywords: پسوریازیس; Psoriasis; Methotrexate; Dermatology life quality index; Psoriasis area and severity index;
Keywords: پسوریازیس; Psoriasis; Dermocorticoides; Metotrexato; Ciclosporina; Acitretina; Fototerapia; Calidad de vida;
Keywords: پسوریازیس; hUCB-MSC; human umbilical cord blood-derived mesenchymal stem cell; IL; interleukin; BMDC; bone marrow-derived dendritic cell; IDO; indoleamine 2,3-dioxygenase; Mesenchymal stem cells; Psoriasis; Skin inflammation; Anti-inflammatory effects;
Keywords: پسوریازیس; psoriasis; psychodermatology; quality of life; skin lesions; social rejection; social stigma; stigmatization; DLQI; Dermatology Life Quality Index; FSQ; Feelings of Stigmatization Questionnaire; HRQoL; health-related quality of life; PASI; Psoriasis Area
Keywords: پسوریازیس; avascular necrosis; comorbidities; inflammation; National Health Insurance Research Database; osteonecrosis; psoriasis; aHR; adjusted hazard ratio; AVN; avascular necrosis; CI; confidence interval; DDD; defined daily doses; HR; hazard ratio; ICD-9-CM; Int
Keywords: پسوریازیس; lichen planus; lichen sclerosus; lichen simplex; psoriasis; vulva; vulval eczema (dermatitis); vulvovaginal candidiasis;
Keywords: پسوریازیس; burden; DLQI; EQ-5D VAS; hidradenitis suppurativa; psoriasis; quality of life; SF-36; TWPI; VAS-pain; DLQI; Dermatology Life Quality Index; EQ-5D; EuroQOL 5D; HRQoL; health-related quality of life; HS; hidradenitis suppurativa; MCS; mental component score
Keywords: پسوریازیس; Psoriasis; HÃgado graso no alcohólico; Esteatosis; Tratamiento; Biológicos; Metotrexato; Psoriasis; Nonalcoholic fatty liver disease; Steatosis; Treatment; Biologic agents; Methotrexate;
Keywords: پسوریازیس; Psoriasis; psoriatic arthritis; autoantigens; IL-17; IL-23; secukinumab; ixekizumab; brodalumab; tildrakizumab, guselkumab, and risankizumab; ADAMTSL5; A disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5; AMP; Antim
Keywords: پسوریازیس; biologic therapy; Crohn's disease; inflammatory bowel disease; interleukin-17 antagonists; ixekizumab; psoriasis; ulcerative colitis; AE; adverse event; CD; Crohn's disease; EPIMAD; Registre Epidemiologique des Maladies de l'Appareil Digestif; IBD; inflam
Keywords: پسوریازیس; comorbidity; database; disease burden; MarketScan; medical insurance claims; psoriasis; CI; confidence interval; ICD-9-CM; International Classification of Diseases, 9th Revision, Clinical Modification; MI; myocardial infarction; THIN; The Health Improveme
Keywords: پسوریازیس; Anti-IL-17 agents; Interleukin-17; Ixekizumab; Psoriasis; Agentes anti IL-17; Interleucina-17; Ixekizumab; Psoriasis;
Keywords: پسوریازیس; Biological therapies; ciclosporin; methotrexate; palmoplantar pustulosis; psoriasis; psoriatic arthritis; pustular psoriasis; treatment; tumour necrosis factor inhibitor;
Keywords: پسوریازیس; biologic; hematologic cancer; malignancy; melanoma; phototherapy; psoriasis; topical therapy; CCI; Charlson comorbidity index; CI; confidence interval; HR; hazard ratio; IL; interleukin; KPSC; Kaiser Permanente Southern California; PUVA; psoralen plus ult
Keywords: پسوریازیس; Innate lymphoid cells; Auto immune diseases; Psoriasis; Inflammatory bowel disease; ILCs; innate lymphoid cells; IBD; inflammatory bowel disease; MS; multiple sclerosis; AS; ankylosing spondylitis; Th; T helper; CLP; common lymphoid progenitor; CD; Crohn'
Keywords: پسوریازیس; Connective tissue diseases; Epigenetics; Rheumatoid arthritis; Psoriasis; Psoriatic arthritis;
Keywords: پسوریازیس; consensus development; medication therapy management; psoriasis; Taiwanese Dermatological Association;
Keywords: پسوریازیس; Antimicrobial peptides; Cathelicidin; Defensins; Immunology; Rosacea; Psoriasis; Atopic dermatitis;
Keywords: پسوریازیس; Urticaria; Angioedema; Psoriasis; Atopic dermatitis; Biologic agents; Omalizumab; Dupilimab;
Keywords: پسوریازیس; Psoriasis; Psoriatic arthritis; Nail abnormality; Hand joint; Ultrasound;
Keywords: پسوریازیس; biologic; conventional systemic; malignancy; methotrexate; psoriasis; PSOLAR; tumor necrosis factor-α inhibitors; TNF-α inhibitors; ustekinumab; CI; confidence interval; NMSC; nonmelanoma skin cancer; OR; odds ratio; PSOLAR; Psoriasis Longitudinal Asses
Keywords: پسوریازیس; completed suicide; meta-analysis; prevalence; psoriasis; suicidal ideation; suicidality; suicide attempts; systematic review; CI; confidence interval; HR; hazard ratio; IL; interleukin; OR; odds ratio;
Keywords: پسوریازیس; Psoriasis; Immunohistochemistry; Thrombogenesis; Tissue factor; Trombomodulin; von Willebrand factor;
Keywords: پسوریازیس; Fluorescence spectroscopy; Basal cell carcinoma; Psoriasis; Bowen's disease;
Keywords: پسوریازیس; Psoriasis; Stem cells; Mesenchymal stem cells;
Keywords: پسوریازیس; Atopic dermatitis; topical treatments; emollients; plaque model; topical calcineurin inhibitor; topical steroids; psoriasis; biomarkers; AD; Atopic dermatitis; DC; Dendritic cell; LC; Langerhans cell; TAA; Target Area Assessment; TCI; Topical calcineurin
Keywords: پسوریازیس; alopecia areata; atopic dermatitis; baricitinib; dermatology; graft versus host disease; JAK inhibitors; psoriasis; ruxolitinib; tofacitinib; vitiligo; AA; alopecia areata; AD; atopic dermatitis; AE; adverse event; CANDLE; chronic atypical neutrophilic de
Keywords: پسوریازیس; Anthralin; Antimicrobial peptides; Cytokeratins; Dithranol; Psoriasis; IL-17; IL-22;
Keywords: پسوریازیس; Thymoquinone; Psoriasis; Lipospheres; Inflammation; Imiquimod induced psoriatic plaque model;